Pharmacokinetics of teicoplanin in patients undergoing chronic haemodialysis. 2002

Maria G Papaioannou, and Smaragda Marinaki, and Michael Pappas, and Dimitrios Stamatiadis, and Evangelos J Giamarellos-Bourboulis, and Helen Giamarellou, and Charalambos Stathakis
4th Department of Internal Medicine, Athens Medical School, Sismanoglion General Hospital, 1 Sismanogliou, Str., 151 26 Maroussi Attikis, Greece.

In order to define a dose regimen of teicoplanin for patients undergoing chronic haemodialysis so that they achieved trough drug serum levels above 10 mg/l, two single doses of 5 and 10 mg/kg were administered intravenously in seven anuric patients immediately after the end of haemodialysis. Concentrations of teicoplanin were determined by a microbiological assay in samples collected from peripheral veins via the arterial and the venous lines of the fistulae and from the dialysate during haemodialysis. The administration of a 5 and 10 mg/kg dose gave mean C(max) of 62.80 and 122.43 mg/l, mean AUC of 526.43 and 1103.98 mg h/l, mean half life (t(1/2)) of 109.09 and 107.06 h, mean clearance rates of 12.85 and 12.44 ml/min, mean apparent volumes of distribution of 1.68 and 1.68 l/kg and mean volumes of distribution at steady state of 0.31 and 0.28 l/kg, respectively. Trough serum levels above 10 mg/l were found for 24 h after the administration of the 5 mg/kg dose and for 48 h after the administration of the 10 mg/kg dose. Teicoplanin was not detected in the dialysate. Its concentrations in both the arterial and the venous lines of the fistulae were similar. Based on the time period after the administration of teicoplanin where the desired trough serum levels were found and on the observed t(1/2), it is proposed that teicoplanin should be administered at a dose of 10 mg/kg at 48-72 h intervals, in patients undergoing chronic haemodialysis for the therapy of infections caused by Gram-positive cocci.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial

Related Publications

Maria G Papaioannou, and Smaragda Marinaki, and Michael Pappas, and Dimitrios Stamatiadis, and Evangelos J Giamarellos-Bourboulis, and Helen Giamarellou, and Charalambos Stathakis
August 1979, European journal of clinical pharmacology,
Maria G Papaioannou, and Smaragda Marinaki, and Michael Pappas, and Dimitrios Stamatiadis, and Evangelos J Giamarellos-Bourboulis, and Helen Giamarellou, and Charalambos Stathakis
January 1982, European journal of drug metabolism and pharmacokinetics,
Maria G Papaioannou, and Smaragda Marinaki, and Michael Pappas, and Dimitrios Stamatiadis, and Evangelos J Giamarellos-Bourboulis, and Helen Giamarellou, and Charalambos Stathakis
January 1994, European journal of clinical pharmacology,
Maria G Papaioannou, and Smaragda Marinaki, and Michael Pappas, and Dimitrios Stamatiadis, and Evangelos J Giamarellos-Bourboulis, and Helen Giamarellou, and Charalambos Stathakis
August 2003, European journal of clinical pharmacology,
Maria G Papaioannou, and Smaragda Marinaki, and Michael Pappas, and Dimitrios Stamatiadis, and Evangelos J Giamarellos-Bourboulis, and Helen Giamarellou, and Charalambos Stathakis
November 2003, Intensive care medicine,
Maria G Papaioannou, and Smaragda Marinaki, and Michael Pappas, and Dimitrios Stamatiadis, and Evangelos J Giamarellos-Bourboulis, and Helen Giamarellou, and Charalambos Stathakis
December 2002, British journal of clinical pharmacology,
Maria G Papaioannou, and Smaragda Marinaki, and Michael Pappas, and Dimitrios Stamatiadis, and Evangelos J Giamarellos-Bourboulis, and Helen Giamarellou, and Charalambos Stathakis
April 1987, Clinical pharmacokinetics,
Maria G Papaioannou, and Smaragda Marinaki, and Michael Pappas, and Dimitrios Stamatiadis, and Evangelos J Giamarellos-Bourboulis, and Helen Giamarellou, and Charalambos Stathakis
January 1989, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Maria G Papaioannou, and Smaragda Marinaki, and Michael Pappas, and Dimitrios Stamatiadis, and Evangelos J Giamarellos-Bourboulis, and Helen Giamarellou, and Charalambos Stathakis
January 1989, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Maria G Papaioannou, and Smaragda Marinaki, and Michael Pappas, and Dimitrios Stamatiadis, and Evangelos J Giamarellos-Bourboulis, and Helen Giamarellou, and Charalambos Stathakis
January 1992, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement,
Copied contents to your clipboard!